Skip to main content
Top
Published in: Current Gastroenterology Reports 3/2016

Open Access 01-03-2016 | Liver (S Cotler and E Kallwitz, Section Editors)

Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature

Authors: Kate Hallsworth, Leah Avery, Michael I. Trenell

Published in: Current Gastroenterology Reports | Issue 3/2016

Login to get access

Abstract

Non-alcoholic fatty liver disease (NAFLD) is largely linked to poor diet, lack of physical activity/exercise, and being overweight. In the absence of approved pharmaceutical agents, lifestyle modification, encompassing dietary change and increased physical activity/exercise to initiate weight loss, is the recommended therapy for NAFLD. Despite this, the use of lifestyle therapy within clinical settings is lacking with limited guidance available about what it should involve, how it should be delivered, and whether it can be feasibly delivered as part of standard care. This paper highlights the evidence for the use of lifestyle modification in NAFLD. While there is evidence to support use of behavioral strategies to support lifestyle behavior change in other clinical populations, these are yet to be assessed in people with NAFLD. However, there is sufficient evidence to suggest that behavioral intervention targeting diet and physical activity to promote weight loss in general is effective and a number of practical strategies are presented on how this could be achieved.
Literature
1.
go back to reference Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatol. 2004;40:1387–95.CrossRef Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatol. 2004;40:1387–95.CrossRef
2.
go back to reference Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol. 2013;28:664–70.CrossRefPubMed Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol. 2013;28:664–70.CrossRefPubMed
3.
go back to reference Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med, J R Coll Physicians. 2006;6:19–25. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med, J R Coll Physicians. 2006;6:19–25.
4.•
go back to reference Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology 2013;10. This article reviews the evidence that suggests NAFLD is a multisystem disease and the factors that might determine interindividual variation in the development and progression of its major hepatic and extrahepatic manifestations (principally Type 2 diabetes mellitus and cardiovascular disease). Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology 2013;10. This article reviews the evidence that suggests NAFLD is a multisystem disease and the factors that might determine interindividual variation in the development and progression of its major hepatic and extrahepatic manifestations (principally Type 2 diabetes mellitus and cardiovascular disease).
5.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol. 1999;116:1413–9.CrossRef Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol. 1999;116:1413–9.CrossRef
6.
go back to reference Ratziu V, Bellentani S, Cortez-Pinto H, Day CP, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.CrossRefPubMed Ratziu V, Bellentani S, Cortez-Pinto H, Day CP, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.CrossRefPubMed
7.
go back to reference Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: a decalogue from the Italian Association for the Study of the Liver (AISF) expert committee. Digestive and Liver Disease. 2010;42:272–82.CrossRefPubMed Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: a decalogue from the Italian Association for the Study of the Liver (AISF) expert committee. Digestive and Liver Disease. 2010;42:272–82.CrossRefPubMed
8.
go back to reference Williams R, Ashton K, Aspinall R, Bellis M, Bosanquet J, Cramp M, et al. Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2015;386:2098–111.CrossRefPubMed Williams R, Ashton K, Aspinall R, Bellis M, Bosanquet J, Cramp M, et al. Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2015;386:2098–111.CrossRefPubMed
9.•
go back to reference Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–66. This systematic review provides evidence that lifestyle interventions designed to reduce energy intake and/or increase energy expenditure reduce liver fat and improve insulin sensitivity in patients with NAFLD.CrossRefPubMed Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–66. This systematic review provides evidence that lifestyle interventions designed to reduce energy intake and/or increase energy expenditure reduce liver fat and improve insulin sensitivity in patients with NAFLD.CrossRefPubMed
10.
go back to reference Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603–8.CrossRefPubMedPubMedCentral Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603–8.CrossRefPubMedPubMedCentral
11.
go back to reference Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterol. 2009;136:1552–60.CrossRef Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterol. 2009;136:1552–60.CrossRef
12.
go back to reference Viljanen APM, Iozzo P, Borra R, Kankaanpää M, Karmi A, Lautamäki R, et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metabolism. 2009;94:50–5.CrossRef Viljanen APM, Iozzo P, Borra R, Kankaanpää M, Karmi A, Lautamäki R, et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metabolism. 2009;94:50–5.CrossRef
13.
go back to reference Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterol. 2015;149:367–78.CrossRef Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterol. 2015;149:367–78.CrossRef
14.
go back to reference Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21:191–8.CrossRefPubMed Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21:191–8.CrossRefPubMed
15.
go back to reference Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatol. 2009;50:1105–12.CrossRef Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatol. 2009;50:1105–12.CrossRef
16.
go back to reference Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci. 2015;129:1097–105.CrossRefPubMed Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci. 2015;129:1097–105.CrossRefPubMed
17.
go back to reference Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–83.CrossRefPubMedPubMedCentral Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–83.CrossRefPubMedPubMedCentral
18.
go back to reference Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44:1203–8.CrossRefPubMed Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44:1203–8.CrossRefPubMed
19.
go back to reference Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, et al. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes. 2010;59:627–33.CrossRefPubMedPubMedCentral Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, et al. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes. 2010;59:627–33.CrossRefPubMedPubMedCentral
20.
go back to reference Promrat K, Kleiner DE, Niemeier H, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatol. 2010;51:121–9.CrossRef Promrat K, Kleiner DE, Niemeier H, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatol. 2010;51:121–9.CrossRef
21.
22.
go back to reference Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatol. 2009;49:80–6.CrossRef Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatol. 2009;49:80–6.CrossRef
23.
go back to reference Department of Health. UK Physical Activity Guidelines. In: Department of Health; 2011. Department of Health. UK Physical Activity Guidelines. In: Department of Health; 2011.
24.
go back to reference ACSM. American College of Sports Medicine Position Stand. Appropriate physical activity intervention for weight loss and weight regain for adults. Med Sci Sports and Exercise. 2009;41:459–71. ACSM. American College of Sports Medicine Position Stand. Appropriate physical activity intervention for weight loss and weight regain for adults. Med Sci Sports and Exercise. 2009;41:459–71.
25.
go back to reference Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet. 1953;265:1053–7.CrossRefPubMed Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet. 1953;265:1053–7.CrossRefPubMed
26.
go back to reference Jonker JT, De Laet C, Franco OH, Peeters A, Mackenbach J, Nusselder WJ. Physical activity and life expectancy with and without diabetes: life table analysis of the Framingham heart study. Diabetes Care. 2006;29:38–43.CrossRefPubMed Jonker JT, De Laet C, Franco OH, Peeters A, Mackenbach J, Nusselder WJ. Physical activity and life expectancy with and without diabetes: life table analysis of the Framingham heart study. Diabetes Care. 2006;29:38–43.CrossRefPubMed
27.
go back to reference Healy GN, Wijndaele K, Dunstan DW, Shaw JE, Salmon J, Zimmet PZ, et al. Objectively measured sedentary time, physical activity, and metabolic risk: the Australian diabetes, obesity and lifestyle study (AusDiab). Diabetes Care. 2008;31:369–71.CrossRefPubMed Healy GN, Wijndaele K, Dunstan DW, Shaw JE, Salmon J, Zimmet PZ, et al. Objectively measured sedentary time, physical activity, and metabolic risk: the Australian diabetes, obesity and lifestyle study (AusDiab). Diabetes Care. 2008;31:369–71.CrossRefPubMed
28.
go back to reference Autenrieth C, Baumert J, Baumeister S, Fischer B, Peters A, Döring A, et al. Association between domains of physical activity and all-cause, cardiovascular and cancer mortality. European J Epidemiol. 2011;26:91–9.CrossRef Autenrieth C, Baumert J, Baumeister S, Fischer B, Peters A, Döring A, et al. Association between domains of physical activity and all-cause, cardiovascular and cancer mortality. European J Epidemiol. 2011;26:91–9.CrossRef
29.
go back to reference Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. New England Journal of Medicine. 2002;347:716–25.CrossRefPubMed Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. New England Journal of Medicine. 2002;347:716–25.CrossRefPubMed
30.
go back to reference Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994–2000.CrossRefPubMed Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994–2000.CrossRefPubMed
31.
go back to reference Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRefPubMed Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRefPubMed
32.
go back to reference DPP. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef DPP. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef
33.
go back to reference Friedenreich CM. Physical activity and cancer prevention. Cancer Epidem Biomark Prev. 2001;10:287–301. Friedenreich CM. Physical activity and cancer prevention. Cancer Epidem Biomark Prev. 2001;10:287–301.
34.•
go back to reference Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, et al. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behavior and lower levels of physical activity than matched healthy controls. Frontline Gastroenterol. 2015;6:44–51. This was the first study to objectively measure sedentary behavior and physical activity in people with NAFLD and investigated links between physical activity levels, liver fat, and glucose control. CrossRefPubMedPubMedCentral Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, et al. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behavior and lower levels of physical activity than matched healthy controls. Frontline Gastroenterol. 2015;6:44–51. This was the first study to objectively measure sedentary behavior and physical activity in people with NAFLD and investigated links between physical activity levels, liver fat, and glucose control. CrossRefPubMedPubMedCentral
35.
go back to reference Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007;30:683–8.CrossRefPubMed Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007;30:683–8.CrossRefPubMed
36.
go back to reference NICE. NICE Clinical Guidelines. CG43 Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. Care NIfHaCEaNCCfP, ed. 2006. NICE. NICE Clinical Guidelines. CG43 Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. Care NIfHaCEaNCCfP, ed. 2006.
37.
go back to reference Ferolla SM, Silva LC, Ferrari Mde L, da Cunha AS, Martins Fdos S, Couto CA, et al. Dietary approach in the treatment of nonalcoholic fatty liver disease. World J Hepatol. 2015;7:2522–34.CrossRefPubMedPubMedCentral Ferolla SM, Silva LC, Ferrari Mde L, da Cunha AS, Martins Fdos S, Couto CA, et al. Dietary approach in the treatment of nonalcoholic fatty liver disease. World J Hepatol. 2015;7:2522–34.CrossRefPubMedPubMedCentral
38.
go back to reference Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4:109–16.PubMedPubMedCentral Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4:109–16.PubMedPubMedCentral
39.
go back to reference Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatol. 2010;51:1961–71.CrossRef Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatol. 2010;51:1961–71.CrossRef
40.
go back to reference Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatol. 2008;48:1791–8.CrossRef Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatol. 2008;48:1791–8.CrossRef
41.
go back to reference Cassidy S, Thoma C, Hallsworth K, Parikh J, Hollingsworth K, Taylor R, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2015:1-11. Cassidy S, Thoma C, Hallsworth K, Parikh J, Hollingsworth K, Taylor R, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2015:1-11.
42.•
go back to reference Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. Journal of Hepatology. 2015;63:174–82. This study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss. CrossRefPubMed Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. Journal of Hepatology. 2015;63:174–82. This study found no difference in efficacy of liver fat reduction by either aerobic exercise dose or intensity. All of the aerobic exercise regimens employed reduced liver fat and VAT by a small amount without clinically significant weight loss. CrossRefPubMed
43.
go back to reference Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015;61:1205–15.CrossRefPubMed Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015;61:1205–15.CrossRefPubMed
44.
go back to reference Bravata DM, Smith-Spanger C, Sundaram V, Gienger AL, Lin N, Lewis R, et al. Using pedometers to increase physical activity and improve health: systematic review. JAMA. 2007;298:2296–304.CrossRefPubMed Bravata DM, Smith-Spanger C, Sundaram V, Gienger AL, Lin N, Lewis R, et al. Using pedometers to increase physical activity and improve health: systematic review. JAMA. 2007;298:2296–304.CrossRefPubMed
45.
go back to reference Michie S, Ashford S, Sniehotta F, Dombrowski S, Bishop A, French D. A refined taxonomy of behavior change techniques to help people change their physical activity and healthy eating behaviors: the CALO-RE taxonomy. Psychol Health. 2011;26:1479–98.CrossRefPubMed Michie S, Ashford S, Sniehotta F, Dombrowski S, Bishop A, French D. A refined taxonomy of behavior change techniques to help people change their physical activity and healthy eating behaviors: the CALO-RE taxonomy. Psychol Health. 2011;26:1479–98.CrossRefPubMed
46.
go back to reference Rollnick S, Mason P. Health behavior change: a guide for practitioners. London: Elsevier; 1999. Rollnick S, Mason P. Health behavior change: a guide for practitioners. London: Elsevier; 1999.
47.•
go back to reference Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012;35(12):2681–9. Diabetes Care 2012;35:2681-2689. This review identified a number of behavior change techniques delivered in clinical and community settings that are associated with increases in physical activity behavior and improvements in glycaemic control in people who are overweight or obese with Type 2 diabetes. CrossRefPubMedPubMedCentral Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012;35(12):2681–9. Diabetes Care 2012;35:2681-2689. This review identified a number of behavior change techniques delivered in clinical and community settings that are associated with increases in physical activity behavior and improvements in glycaemic control in people who are overweight or obese with Type 2 diabetes. CrossRefPubMedPubMedCentral
48.
go back to reference Avery L, Flynn D, Dombrowski SU, Wan Wersch A, Sniehotta FF, Trenell MI. Successful behavioral strategies to increase physical activity and improve glucose control in adults with type 2 diabetes. Diabetic Medicine. 2015;32:1058–62.CrossRefPubMed Avery L, Flynn D, Dombrowski SU, Wan Wersch A, Sniehotta FF, Trenell MI. Successful behavioral strategies to increase physical activity and improve glucose control in adults with type 2 diabetes. Diabetic Medicine. 2015;32:1058–62.CrossRefPubMed
49.
go back to reference French DP, Stevenson A, Michie S. An intervention to increase walking requires both motivational and volitional components: a replication and extension. Psychol Health Med. 2012;17:127–35.CrossRefPubMed French DP, Stevenson A, Michie S. An intervention to increase walking requires both motivational and volitional components: a replication and extension. Psychol Health Med. 2012;17:127–35.CrossRefPubMed
50.
go back to reference Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011;11:119.CrossRefPubMedPubMedCentral Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011;11:119.CrossRefPubMedPubMedCentral
51.
go back to reference Sniehotta F, Scholz U, Schwarzer R. Action plans and coping plans for physical exercise: a longitudinal intervention study in cardiac rehabilitation. Br J Health Psychol. 2006;11:23–37.CrossRefPubMed Sniehotta F, Scholz U, Schwarzer R. Action plans and coping plans for physical exercise: a longitudinal intervention study in cardiac rehabilitation. Br J Health Psychol. 2006;11:23–37.CrossRefPubMed
52.
go back to reference Kwasnicka D, Presseau J, White M, Sniehotta F. Does planning how to cope with anticipated barriers facilitate health-related behavior change? A systematic review. Health Psychol Rev. 2013;7:129–45.CrossRef Kwasnicka D, Presseau J, White M, Sniehotta F. Does planning how to cope with anticipated barriers facilitate health-related behavior change? A systematic review. Health Psychol Rev. 2013;7:129–45.CrossRef
Metadata
Title
Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature
Authors
Kate Hallsworth
Leah Avery
Michael I. Trenell
Publication date
01-03-2016
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 3/2016
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0485-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.